Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patients find CAC more persuasive than ASCVD risk score for statin decisions

Publish date:: May 29, 2020

Key clinical point: Patients find a high coronary artery calcium score more believable than the results of the Pooled Cohort Equations Risk Calculator.

Major finding: Patients were twice as likely to initiate statin therapy for primary cardiovascular prevention if the recommendation was based on a coronary artery calcium score rather than the Pooled Cohort Equations Risk Calculator.

Study details: The CorCal Vanguard study was a primary cardiovascular prevention trial including 601 patients randomized to the American College of Cardiology/American Heart Association Pooled Cohort Equations or coronary artery calcium score as the basis for making a recommendation for initiation of statin therapy.

Disclosures: The presenter reported having no financial conflicts regarding the CorCal study, funded by a grant from the Dell Loy Hansen Cardiovascular Research Fund.

Citation:

Muhlestein JB et al. ACC 2020, Abstract 909-12.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,